View More Recent Stories

May 14, 2020 08:18AM Frequency Therapeutics (FREQ) Provides Clinical Data from Exploratory Study Confirming Delivery of FX-322 to Cochlea
May 14, 2020 07:30AM Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results
May 14, 2020 07:15AM Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea
Mar 26, 2020 07:00AM Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 21, 2020 08:30AM Frequency Therapeutics to Present at the 40th Annual Cowen Healthcare Conference
Feb 7, 2020 08:00AM Frequency Therapeutics Expands Leadership Team with Newly Appointed Chief People Officer and Head of Intellectual Property
Jan 7, 2020 09:00AM Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference
Nov 18, 2019 07:30AM Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results
Oct 10, 2019 08:35AM Frequency Therapeutics (FREQ) Begins Dosing in Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation
Oct 10, 2019 08:30AM Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation
View More Recent Stories